Derive has proposed upgrading its Derive Chain to V3, an options exchange that will settle trades on Ethereum and offer its trading infrastructure to other crypto apps. The V3 upgrade plans to handle order matching offchain using a zkVM, while Ethereum Layer 1 verifies proofs for trade settlement. User funds will remain secured in Ethereum contracts, and state data will be posted to Celestia. The proposal includes migrating existing V2 balances without requiring withdrawals, and winding down Derive Chain after migration. Markets will be organized into four risk groups, and new developer tools will enable easier vault deployment, borrowing, and margin controls. The upgrade aims to make Derive a shared API and settlement layer for other applications, pending a governance vote and migration schedule confirmation.
Derive's proposal for an Ethereum settlement upgrade to its V3 options exchange is the subject here, with Pluang's market snapshot providing context. As of Oct 02, 2026 01:41 WIB, among 50 major cryptocurrencies priced on Pluang, 29 rose and 20 fell. Notable movers include DOT at Rp21.303 with a 1-day change of -3.71% and a typical hold time of 121 days, COMP at Rp429.188 down 3.70% with a 97-day hold, and THETA at Rp3.955 down 3.63% with a 77-day hold.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
